LIXTE Biotechnology Joins Russell Microcap Index, Boosting Visibility Among Institutional Investors

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced today that it has been added to the Russell Microcap(R) Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The inclusion in this widely followed benchmark is expected to increase the company's visibility among institutional investors and investment products that track Russell indexes, according to the company.

The milestone reflects progress under LIXTE's new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies, providing a benchmark for micro-cap stocks.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that LB-100, its lead compound and first-in-class clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.

Through LIXTE's wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora's proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

The inclusion in the Russell Microcap Index is a significant step for LIXTE as it seeks to broaden its investor base and enhance its profile in the financial community. The index is widely used by investment managers and institutional investors for portfolio benchmarking and as a basis for index-linked investment products. By joining the index, LIXTE may attract increased attention from funds that track the Russell Microcap Index, potentially leading to greater liquidity and market recognition.

For more information about LIXTE Biotechnology Holdings, Inc., including the latest news and updates, visit the company's newsroom at https://ibn.fm/LIXT.